What are the possible side effects of using caposetinib/caposetinib?

Capivasertib is an oral targeted drug that is an AKT kinase inhibitor and is widely used in the treatment of advanced or metastatic breast cancer related to PIK3CA, AKT1 or PTEN gene abnormalities, especially for hormone receptor-positive, HER2-negative patients. Although the drug shows significant potential in improving tumor response, it may still cause a variety of side effects during use, which requires high concern from patients and doctors.

One of the most common adverse reactions is gastrointestinal symptoms, especially diarrhea. As a kinase inhibitor, capositinib affects the renewal mechanism of intestinal epithelial cells, causing frequent diarrhea. Some patients require auxiliary intervention with antidiarrheal drugs. In addition, nausea, vomiting, and loss of appetite are also common, which may affect the patient's eating and nutritional intake.

Skin-related reactions are another broad category of side effects and include rash, dry skin, itching, and pigmentation abnormalities. Some patients may develop facial and upper body skin rashes in the early or middle stages of treatment, which is closely related to the effect of the drug on epidermal cells. It is recommended to use moisturizer and avoid strong sun exposure to reduce skin discomfort.

Hyperglycemia and metabolic disorders are also issues that require close monitoring during capositinib treatment. Since theAKT signaling pathway plays a role in regulating insulin sensitivity, this drug may interfere with glucose metabolism and lead to an increase in blood sugar. In particular, patients with diabetes or abnormal glucose tolerance need to pay special attention to blood sugar monitoring.

In addition, fatigue and weakness are one of the more common side effects, which may affect patients' ability to perform daily activities. Some people may also experience stomatitis, alopecia, liver function abnormalities, leukopenia, etc. Although most of these reactions are controllable, the need to adjust the dose or suspend treatment should be assessed based on individual circumstances.

Reference materials:https://www.drugs.com/mtm/capivasertib.html